Efficacy of Zolmitriptan (Zomig) in the treatment of migraines in adolescents

Study identifier:D1221C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study with Single-blind, Placebo-challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the treatment of Acute Migraine Headache in Adolescents.

Medical condition

migraine

Phase

Phase 3

Healthy volunteers

No

Study drug

Zolmitriptan, Placebo

Sex

All

Actual Enrollment

247

Study type

Interventional

Age

12 Years - 17 Years

Date

Study Start Date: 01 Sept 2003
Primary Completion Date: -
Study Completion Date: 01 Oct 2004

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria